First release of platform enables research organizations to follow COVID-19 symptoms for their ongoing and future clinical trials, and advance scientific understanding of the virus.
NEW YORK–(BUSINESS WIRE)– Medidata, a Dassault Systèmes company, announced the launch of myMedidata, an advanced, intuitive platform and app for patients to enable flexible participation in clinical trials for new medicines and vaccines. myMedidata provides a unified experience for patients, encompassing all of the capabilities of Medidata’s industry-leading, regulatory-compliant Rave platform and Patient Cloud tools.
This first release of myMedidata includes a research-based COVID-19 symptom tracker, that is designed to support research studies and advance scientific understanding of the virus. It will be made available to Medidata customers free of charge.
This app will provide sponsors the ability to collect symptoms directly from research participants who may not otherwise be able to continue with traditional site visits. It also allows researchers to recruit large registries of individuals to monitor their health status with respect to COVID.
myMedidata provides an integrated tool set for all aspects of patient-centered research. This includes eConsent (an electronic patient consent system for clinical trial participation), eCOA (electronic clinical outcomes assessment) / ePRO (electronic patient-reported outcomes), Wearable Sensors (collecting data from biosensors and wearable technology) and Virtual Trials.
This virtualization of clinical trials – using patient-facing technologies to allow clinical research to be conducted remotely – is essential in the current healthcare environment. A recent White Paper, COVID-19 and Clinical Trials: The Medidata Perspective, demonstrates the effect of lock-downs and quarantines on new patients entering clinical trials for actively recruiting studies, and how digital solutions can mitigate those issues to support the continuation of those studies.
myMedidata was built using insights generated by the company’s Patient Centricity by Design framework, where patient advocates regularly engage as a part of the Medidata software design and development life cycle. The new platform provides patients the opportunity to view their own clinical data (current and historical) and increases their engagement with the study team.
Medidata is a wholly-owned subsidiary of Dassault Systèmes. For more information, see medidata.com.
Contacts
Caroline Drucker
Senior Director, Corporate Communications
347-675-3222
cdrucker@medidata.com
